Comparison of the course of biomarker changes and kidney injury in a rat model of drug-induced acute kidney injury

Biomarkers

Volumn 16, Issue 7, 2011, Pages 553-566

  Sasaki, Daisuke ^a   Yamada, Atsushi ^a   Umeno, Hitomi ^a   Kurihara, Hiroshi ^a   Nakatsuji, Shunji ^a   Fujihira, Shiro ^a   Tsubota, Kenjiro ^a   Ono, Mihoko ^a   Moriguchi, Akira ^a   Watanabe, Kouji ^a   Seki, Jiro ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

2 bromoethylamine; cisplatin; gentamicin; puromycin; renal disease; renal toxicity

Indexed keywords

2 BROMOETHYLAMINE; ALBUMIN; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CALBINDIN; CISPLATIN; CLUSTERIN; CREATININE; CYSTATIN C; EPIDERMAL GROWTH FACTOR; GENTAMICIN; GLUTATHIONE TRANSFERASE ALPHA; GLUTATHIONE TRANSFERASE MU; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OSTEOPONTIN; PROTEIN KIM 1; PROTEIN RPA 1; PUROMYCIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CREATININE BLOOD LEVEL; MALE; NONHUMAN; RAT; SENSITIVITY AND SPECIFICITY; UREA NITROGEN BLOOD LEVEL;

ACUTE KIDNEY INJURY; ANIMALS; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; BLOOD UREA NITROGEN; CALCIUM-BINDING PROTEIN, VITAMIN D-DEPENDENT; CELL ADHESION MOLECULES; CISPLATIN; CLUSTERIN; CREATININE; CYSTATIN C; ETHYLAMINES; GENTAMICINS; KIDNEY; MALE; PUROMYCIN; RATS; RATS, SPRAGUE-DAWLEY; SENSITIVITY AND SPECIFICITY;

RATTUS;

EID: 80054914162     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2011.613123     Document Type: Article

References (41)

1. Ali BH. (2003). Agents ameliorating or augmenting experimental gentamicin nephrotoxicity: some recent research. Food Chem Toxicol 41:1447-1452.
2. Aulitzky WK, Schlegel PN, Wu DF, Cheng CY, Chen CL, Li PS, Goldstein M, Reidenberg M, Bardin CW. (1992). Measurement of urinary clusterin as an index of nephrotoxicity. Proc Soc Exp Biol Med 199:93-96.
3. Barnes DW. (1982). Epidermal growth factor inhibits growth of A431 human epidermoid carcinoma in serum-free cell culture. J Cell Biol 93:1-4.
4. Bernard A, Viau C, Ouled A, Tulkens P, Lauwerys R. (1986). Effects of gentamicin on the renal uptake of endogenous and exogenous protein in conscious rats. Toxicol Appl Pharmacol 84:431-438. (Pubitemid 16067190)
5. Bolisetty S, Agarwal A. (2011). Urine albumin as a biomarker in acute kidney injury. Am J Physiol Renal Physiol 300:F626-F627.
6. Bonventre JV, Vaidya VS, Schmouder R, Feig P, Dieterle F. (2010). Nextgeneration biomarkers for detecting kidney toxicity. Nat Biotechnol 28:436-440.
7. Brix AE. (2002). Renal papillary necrosis. Toxicol Pathol 30:672-674.
8. Clavant SP, Greive KA, Nikolovski J, Reeve S, Smith AI, Comper WD. (2003). Albumin fragments in normal rat urine are derived from rapidly degraded filtered albumin. Nephrology (Carlton) 8:72-79. (Pubitemid 36535248)
9. Cuttino JT Jr, Goss FU, Clark RL, Marr MC. (1981). Experimental renal papillary necrosis in rats: microangiographic and tubular micropuncture injection studies. Invest Radiol 16:107-114. (Pubitemid 11102672)
10. Dieterle F, Perentes E, Cordier A, Roth DR, Verdes P, Grenet O, Pantano S, Moulin P, Wahl D, Mahl A, End P, Staedtler F, Legay F, Carl K, Laurie D, Chibout SD, Vonderscher J, Maurer G. (2010a). Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury. Nat Biotechnol 28:463-469.
11. Dieterle F, Sistare F, Goodsaid F, Papaluca M, Ozer JS, Webb CP, Baer W, Senagore A, Schipper MJ, Vonderscher J, Sultana S, Gerhold DL, Phillips JA, Maurer G, Carl K, Laurie D, Harpur E, Sonee M, Ennulat D, Holder D, Andrews-Cleavenger D, Gu YZ, Thompson KL, Goering PL, Vidal JM, Abadie E, Maciulaitis R, Jacobson- Kram D, Defelice AF, Hausner EA, Blank M, Thompson A, Harlow P, Throckmorton D, Xiao S, Xu N, Taylor W, Vamvakas S, Flamion B, Lima BS, Kasper P, Pasanen M, Prasad K, Troth S, Bounous D, Robinson-Gravatt D, Betton G, Davis MA, Akunda J, McDuffie JE, Suter L, Obert L, Guffroy M, Pinches M, Jayadev S, Blomme EA, Beushausen SA, Barlow VG, Collins N, Waring J, Honor D, Snook S, Lee J, Rossi P, Walker E, Mattes W. (2010b). Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nat Biotechnol 28:455-462.
12. European-Medicines-Agency. (2010). Qualification Opinion ILSI/HESI Submission of Novel Renal Biomarkers for Toxicity. [online] Available at: http://www.ema.europa.eu/docs/en-GB/document-library/ Regulatory-and-procedural- guideline/2010/11/WC500099359.pdf.
13. Falkenberg FW, Hildebrand H, Lutte L, Schwengberg S, Henke B, Greshake D, Schmidt B, Friederich A, Rinke M, Schlüter G, Bomhard E. (1996). Urinary antigens as markers of papillary toxicity. I. Identification and characterization of rat kidney papillary antigens with monoclonal antibodies. Arch Toxicol 71:80-92. (Pubitemid 26402873)
14. Gautier JC, Riefke B, Walter J, Kurth P, Mylecraine L, Guilpin V, Barlow N, Gury T, Hoffman D, Ennulat D, Schuster K, Harpur E, Pettit S. (2010). Evaluation of novel biomarkers of nephrotoxicity in two strains of rat treated with Cisplatin. Toxicol Pathol 38:943-956.
15. Harpur E, Ennulat D, Hoffman D, Betton G, Gautier JC, Riefke B, Bounous D, Schuster K, Beushausen S, Guffroy M, Shaw M, Lock E, Pettit S; on behalf of the HESI Committee on Biomarkers of Nephrotoxicity. (2011). Biological Qualification of Biomarkers of Chemical-Induced Renal Toxicity in Two Strains of Male Rat. Toxicol Sci 122:235-252.
16. Hayes JD. (1983). Rat liver glutathione S-transferases. A study of the structure of the basic YbYb-containing enzymes. Biochem J 213:625-633.
17. Hewitt P, Herget T. (2009). Value of new biomarkers for safety testing in drug development. Expert Rev Mol Diagn 9:531-536.
18. Hildebrand H, Rinke M, Schlüter G, Bomhard E, Falkenberg FW. (1999). Urinary antigens as markers of papillary toxicity. II: Application of monoclonal antibodies for the determination of papillary antigens in rat urine. Arch Toxicol 73:233-245. (Pubitemid 29356687)
19. Hoffmann D, Adler M, Vaidya V, Rached E, Mulrane L, Gallagher WM, Callanan JJ, Gautier JC, Matheis K, Staedtler F, Dieterle F, Brandenburg A, Sposny A, Hewitt P, Ellinger-Ziegelbauer H, Bonventre JV, Dekant W, Mally A. (2010). Performance of novel kidney biomarkers in preclinical toxicity studies. Toxicol Sci 116:8-22.
20. Houghton DC, Hartnett M, Campbell-Boswell M, Porter G, Bennett W. (1976). A light and electron microscopic analysis of gentamicin nephrotoxicity in rats. Am J Pathol 82:589-612.
21. Iglesias J, Levine JS. (2001). Albuminuria and renal injury-beware of proteins bearing gifts. Nephrol Dial Transplant 16:215-218. (Pubitemid 32123903)
22. Kania K, Byrnes EA, Beilby JP, Webb SA, Strong KJ. (2010). Urinary proteases degrade albumin: implications for measurement of albuminuria in stored samples. Ann Clin Biochem 47:151-157.
23. Khan KN, Alden CL, Gleissner SE, Gessford MK, Maziasz TJ. (1998). Effect of papillotoxic agents on expression of cyclooxygenase isoforms in the rat kidney. Toxicol Pathol 26:137-142. (Pubitemid 28100698)
24. Kishore BK, Gejyo F, Arakawa M. (1983). Alpha 2HS-glycoprotein in the serum and urine of patients with renal diseases. Postgrad Med J 59:304-307. (Pubitemid 13079856)
25. Kramer JA, Pettit SD, Amin RP, Bertram TA, Car B, Cunningham M, Curtiss SW, Davis JW, Kind C, Lawton M, Naciff JM, Oreffo V, Roman RJ, Sistare FD, Stevens J, Thompson K, Vickers AE, Wild S, Afshari CA. (2004). Overview on the application of transcription profiling using selected nephrotoxicants for toxicology assessment. Environ Health Perspect 112:460-464. (Pubitemid 38404557)
26. Murray G, Wyllie RG, Hill GS, Ramsden PW, Heptinstall RH. (1972). Experimental papillary necrosis of the kidney I. Morphologic and functional data. Am J Pathol 67:285-302.
27. Pabla N, Dong Z. (2008). Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73:994-1007. (Pubitemid 351543900)
28. Price SA, Davies D, Rowlinson R, Copley CG, Roche A, Falkenberg FW, Riccardi D, Betton GR. (2010). Characterization of renal papillary antigen 1 (RPA-1), a biomarker of renal papillary necrosis. Toxicol Pathol 38:346-358.
29. Rached E, Hoffmann D, Blumbach K, Weber K, Dekant W, Mally A. (2008). Evaluation of putative biomarkers of nephrotoxicity after exposure to ochratoxin a in vivo and in vitro. Toxicol Sci 103:371-381. (Pubitemid 351659609)
30. Safirstein R, Zelent AZ, Price PM. (1989). Reduced renal preproepidermal growth factor mRNA and decreased EGF excretion in ARF. Kidney Int 36:810-815. (Pubitemid 19283279)
31. Sieber M, Hoffmann D, Adler M, Vaidya VS, Clement M, Bonventre JV, Zidek N, Rached E, Amberg A, Callanan JJ, Dekant W, Mally A. (2009). Comparative analysis of novel noninvasive renal biomarkers and metabonomic changes in a rat model of gentamicin nephrotoxicity. Toxicol Sci 109:336-349.
32. Sistare FD, Dieterle F, Troth S, Holder DJ, Gerhold D, Andrews- Cleavenger D, Baer W, Betton G, Bounous D, Carl K, Collins N, Goering P, Goodsaid F, Gu YZ, Guilpin V, Harpur E, Hassan A, Jacobson-Kram D, Kasper P, Laurie D, Lima BS, Maciulaitis R, Mattes W, Maurer G, Obert LA, Ozer J, Papaluca-Amati M, Phillips JA, Pinches M, Schipper MJ, Thompson KL, Vamvakas S, Vidal JM, Vonderscher J, Walker E, Webb C, Yu Y. (2010). Towards consensus practices to qualify safety biomarkers for use in early drug development. Nat Biotechnol 28:446-454.
33. Tabata H, Nakatsuji S, Sasaki D, Seki J, Oishi Y, Miyamae Y, Watanabe K, Kurata M, Hirasawa Y, Morimoto K, Shimomi A. (2009). Urinary renal papillary antigen-1 (RPA-1) is a sensitive biomarker for gauging collecting duct responsiveness to a vasopressin V2 agonist in rats J Toxicol Sci 34: S117.
34. Thielemans N, Lauwerys R, Bernard A. (1994). Competition between albumin and low-molecular-weight proteins for renal tubular uptake in experimental nephropathies. Nephron 66:453-458. (Pubitemid 24083592)
35. Thukral SK, Nordone PJ, Hu R, Sullivan L, Galambos E, Fitzpatrick VD, Healy L, Bass MB, Cosenza ME, Afshari CA. (2005). Prediction of nephrotoxicant action and identification of candidate toxicity-related biomarkers. Toxicol Pathol 33:343-355. (Pubitemid 40617138)
36. Vaidya VS, Ramirez V, Ichimura T, Bobadilla NA, Bonventre JV. (2006). Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol 290:F517-F529. (Pubitemid 43725006)
37. Ware LB, Johnson AC, Zager RA. (2011). Renal cortical albumin gene induction and urinary albumin excretion in response to acute kidney injury. Am J Physiol Renal Physiol 300:F628-F638.
38. Yao X, Panichpisal K, Kurtzman N, Nugent K. (2007). Cisplatin nephrotoxicity: a review. Am J Med Sci 334:115-124. (Pubitemid 47262919)
39. Zhang J, Brown RP, Shaw M, Vaidya VS, Zhou Y, Espandiari P, Sadrieh N, Stratmeyer M, Keenan J, Kilty CG, Bonventre JV, Goering PL. (2008). Immunolocalization of Kim-1, RPA-1, and RPA-2 in kidney of gentamicin-, mercury-, or chromium-treated rats: relationship to renal distributions of iNOS and nitrotyrosine. Toxicol Pathol 36:397-409.
40. Zhang J, Goering PL, Espandiari P, Shaw M, Bonventre JV, Vaidya VS, Brown RP, Keenan J, Kilty CG, Sadrieh N, Hanig JP. (2009). Differences in immunolocalization of Kim-1, RPA-1, and RPA-2 in kidneys of gentamicin-, cisplatin-, and valproic acid-treated rats: potential role of iNOS and nitrotyrosine. Toxicol Pathol 37:629-643.
41. Zhou H, Pisitkun T, Aponte A, Yuen PS, Hoffert JD, Yasuda H, Hu X, Chawla L, Shen RF, Knepper MA, Star RA. (2006). Exosomal Fetuin-A identified by proteomics: a novel urinary biomarker for detecting acute kidney injury. Kidney Int 70:1847-1857. (Pubitemid 44684818)